Clinical analysis of 20 patients with primary non-Hodgkin's lymphoma of nasal cavity and nasopharynx.
- Author:
ABULAJIANG
1
;
YOULEDUSI
2
;
Xingzhi GU
2
Author Information
1. Department of Otolaryngology, Xinjiang Uygur Autonomous Region People's Hospital, Urumqi, 830054, China. abulajiang6462@sina.cn
2. Department of Otolaryngology, Xinjiang Uygur Autonomous Region People's Hospital, Urumqi, 830054, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Female;
Humans;
Lymphoma, Non-Hodgkin;
therapy;
Male;
Nasal Cavity;
Nasopharyngeal Neoplasms;
therapy;
Nose Neoplasms;
therapy;
Retrospective Studies;
Survival Rate
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2013;27(18):1006-1008
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the treatment policy for non-Hodgkin's lymphoma of the nasal cavity and nasopharynx.
METHOD:Twenty patients with pathologically confirmed non-Hodgkin's lymphoma of nasal cavity and nasopharynx,treated from Jan. 2006 to Oct. 2010, were retrospectively reviewed.
RESULT:The 3-year overall survival and complete response rates for all patients were 78% and 47% respectively. The 3-year overall survival rates for patients treated with chemotherapy and patients treated with chemotherapy plus radiotherapy were 75% and 82% respectively. The estimates of complete response for patients receiving chemotherapy alone and for patients receiving chemotherapy plus radiotherapy were 37% and 55%, respectively. The 3-year overall survival rates for patients who achieved complete response and patients who did not were 89% and 70%, respectively. The 3-year overall survival rates for patients in stage IE and stage II E were 92% and 57%, respectively.
CONCLUSION:There was no significant difference between chemotherapy alone and chemotherapy plus radiotherapy for the treatment of non-Hodgkin's lymphoma of the nasal cavity and nasopharynx. The 3-year overall survival rate for patients in stage IE was much higher than in stage II E. Early treatment is very important to improve the survival rate of the patients.
